CAPRISA 004 is the name of a clinical trial conducted by CAPRISA. This particular study was the first to show that a topical gel could reduce a person's risk of contracting HIV. The gel used in the study contained a microbicide.
CAPRISA 004 és el nom de l'assig clínic dut a terme pel Centre for the AIDS Programme of Research in South Africa conegut com a CAPRISA. El títol oficial de l'estudi era «Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa». En concret, aquest estudi intentava demostrar l'eficàcia d'un gel com a mecanisme per a reduir la probabilitat d'infectar-se pel VIH durant una relació coital. El component clau d'aquest gel era una microbicida. (ca)
CAPRISA 004 is the name of a clinical trial conducted by CAPRISA. This particular study was the first to show that a topical gel could reduce a person's risk of contracting HIV. The gel used in the study contained a microbicide. (en)
CAPRISA 004 és el nom de l'assig clínic dut a terme pel Centre for the AIDS Programme of Research in South Africa conegut com a CAPRISA. El títol oficial de l'estudi era «Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa». En concret, aquest estudi intentava demostrar l'eficàcia d'un gel com a mecanisme per a reduir la probabilitat d'infectar-se pel VIH durant una relació coital. El component clau d'aquest gel era una microbicida. (ca)
CAPRISA 004 is the name of a clinical trial conducted by CAPRISA. This particular study was the first to show that a topical gel could reduce a person's risk of contracting HIV. The gel used in the study contained a microbicide. (en)